Insider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 14,240 Shares of Stock

Key Points

• Reprogrammed Interchange LLC sold a total of 284,805 shares of Vor Biopharma at an average price of $1.83, resulting in proceeds of approximately $521,193.15, and now holds 33,928,487 shares valued at about $62 million.
• Vor Biopharma's stock price has dropped 8.0% recently, trading at $1.60, amid significant trading volume of 6,009,423 shares.
• Several institutional investors have recently increased their stakes in Vor Biopharma, with 97.29% of the stock now held by hedge funds and other institutions.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 14,240 shares of the business's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $36.60, for a total transaction of $521,184.00. Following the completion of the sale, the insider directly owned 1,696,424 shares in the company, valued at approximately $62,089,118.40. This represents a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The stock was sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total transaction of $898,440.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $39.40, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 22,650 shares of Vor Biopharma stock. The stock was sold at an average price of $38.60, for a total transaction of $874,290.00.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 27,730 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total transaction of $1,109,200.00.

Vor Biopharma Stock Down 10.4%

Shares of VOR traded down $3.16 during trading hours on Friday, hitting $27.24. The company had a trading volume of 654,392 shares, compared to its average volume of 380,475. The firm has a market cap of $3.45 billion, a price-to-earnings ratio of -16.51 and a beta of 2.05. The business has a fifty day moving average of $40.37 and a 200-day moving average of $22.88. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on VOR. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Vor Biopharma in a research report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $121.33.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently modified their holdings of VOR. Northern Trust Corp grew its stake in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. Trustees of Columbia University in the City of New York acquired a new position in shares of Vor Biopharma in the fourth quarter valued at about $102,000. Two Sigma Investments LP grew its stake in Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after buying an additional 25,930 shares in the last quarter. Money Concepts Capital Corp grew its stake in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after buying an additional 26,535 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma during the first quarter worth about $100,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.